Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.

Xuan M, Xue F, Fu R, Yang Y, Zhang L, Tian M, Yang R.

J Thromb Thrombolysis. 2014 Jul;38(1):92-7. doi: 10.1007/s11239-013-1009-6.

PMID:
24197652
2.

Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).

Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.

Haemophilia. 2011 May;17(3):407-11. doi: 10.1111/j.1365-2516.2010.02430.x. Epub 2011 Mar 8.

PMID:
21382134
3.

Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.

Batorova A, Jankovicova D, Morongova A, Bubanska E, Prigancova T, Horakova J, Machyniakova M, Cervenka J, Chandoga J, Böhmer D, Mistrik M.

Semin Thromb Hemost. 2016 Jul;42(5):550-62. doi: 10.1055/s-0036-1581107. Epub 2016 May 28.

PMID:
27235830
4.

Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.

Montalvão SA, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC.

Haemophilia. 2015 Jul;21(4):e281-5. doi: 10.1111/hae.12647. Epub 2015 Apr 30.

PMID:
25929310
5.
7.

Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.

Rea C, Dunkerley A, Sørensen B, Rangarajan S.

Haemophilia. 2009 Nov;15(6):1237-42. doi: 10.1111/j.1365-2516.2009.02071.x. Epub 2009 Aug 2.

PMID:
19664015
8.

Risk of inhibitor development in mild haemophilia A increases with age.

Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K.

Haemophilia. 2012 Mar;18(2):263-7. doi: 10.1111/j.1365-2516.2011.02629.x. Epub 2011 Aug 19.

PMID:
21851507
9.

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.

Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P; ReFacto-AICE Study Group.

Br J Haematol. 2004 Aug;126(3):398-404.

PMID:
15257713
10.

Forum on: the role of recombinant factor VIII in children with severe haemophilia A.

Franchini M, Coppola A, Molinari AC, Santoro C, Schinco P, Speciale V, Tagliaferri A.

Haemophilia. 2009 Mar;15(2):578-86. doi: 10.1111/j.1365-2516.2008.01975.x. Epub 2009 Feb 1.

PMID:
19187188
11.

Frequency of factor VIII (FVIII) inhibitor in haemophilia A.

Borhany M, Kumari M, Shamsi T, Naz A, Farzana T.

J Coll Physicians Surg Pak. 2012 May;22(5):289-93. doi: 05.2012/JCPSP.289293.

PMID:
22538032
12.

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.

Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E; KOGENATE Bayer European PMS Study Group.

Thromb Haemost. 2008 Jan;99(1):52-8. doi: 10.1160/TH07-06-0409.

PMID:
18217134
13.

[Inhibitor development after changing FVIII/IX products in patients with haemophilia].

Kocher S, Asmelash G, Makki V, Müller S, Krekeler S, Alesci S, Miesbach W.

Hamostaseologie. 2012;32 Suppl 1:S39-42. German.

PMID:
22961330
14.
15.

Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.

Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G.

Haemophilia. 2011 Jul;17(4):625-9. doi: 10.1111/j.1365-2516.2010.02464.x. Epub 2011 Feb 7.

PMID:
21299743
16.

Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.

Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R.

Haemophilia. 2011 Mar;17(2):191-5. doi: 10.1111/j.1365-2516.2010.02395.x. Epub 2010 Sep 22.

PMID:
20860578
17.

Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.

Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A.

Haemophilia. 2009 May;15(3):676-85. doi: 10.1111/j.1365-2516.2008.01978.x. Epub 2009 Feb 27.

PMID:
19298381
18.

Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.

Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, Ishiguro N.

Haemophilia. 2015 May;21(3):374-9. doi: 10.1111/hae.12611. Epub 2014 Dec 18.

PMID:
25521821
19.

Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands.

Eckhardt CL, Mauser-Bunschoten EP, Peters M, Leebeek FW, van der Meer FJ, Fijnvandraat K.

Br J Haematol. 2012 Jun;157(6):747-52. doi: 10.1111/j.1365-2141.2012.09119.x. Epub 2012 Apr 26.

PMID:
22533635
20.

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.

Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group.

Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.

Supplemental Content

Support Center